| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Isecarosmab Basic information |
| Product Name: | Isecarosmab | | Synonyms: | Isecarosmab;Research Grade Isecarosmab (DHK09401);Research Grade Isecarosmab | | CAS: | 2254082-79-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Isecarosmab Structure]() |
| | Isecarosmab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Isecarosmab Usage And Synthesis |
| Uses | Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life[1][2][3]. | | in vivo | Isecarosmab (0.1-10 mg/kg mg/kg, s.c, every third day) decreases the medial cartilage degeneration in Medial meniscus (DMM) mice[1].
| | References | [1] Siebuhr AS, et al. The Anti-ADAMTS-5 Nanobody M6495 Protects Cartilage Degradation Ex Vivo. Int J Mol Sci. 2020 Aug 20;21(17):5992. DOI:10.3390/ijms21175992
[2] Sharma N, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2020 May;28(5):658-668. DOI:10.1016/j.joca.2019.11.002
[3] C. Brenneis. Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). 2018. 26 (1), S299-S300. |
| | Isecarosmab Preparation Products And Raw materials |
|